Truist analyst David MacDonald downgraded Molina Healthcare (MOH) to Hold from Buy with a price target of $180, down from $335. The company’s Q2 results and reduced outlook were impacted by accelerating medical cost pressures across all business lines, the analyst tells investors in a research note. The firm cites the challenging medical cost trend environment for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare price target lowered to $186 from $270 at Barclays
- Molina Healthcare price target lowered to $179 from $373 at Baird
- Cantor downgrades Molina to Neutral on Medicaid uncertainty
- Molina Healthcare Reports Q2 2025 Financial Results
- Molina Healthcare Earnings Call: Mixed Sentiment Amid Growth